INCY Share Price

Open 114.36 Change Price %
High 115.48 1 Day -4.20 -3.65
Low 110.65 1 Week -8.30 -6.97
Close 110.85 1 Month -12.80 -10.35
Volume 2174100 1 Year 21.87 24.58
52 Week High 153.15
52 Week Low 83.01
INCY Important Levels
Resistance 2 115.33
Resistance 1 113.48
Pivot 112.33
Support 1 108.22
Support 2 106.37
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
LOCM 0.09 50.00%
NETE 0.72 44.00%
SCHS 0.04 33.33%
MRGE 0.55 30.95%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PGRX 0.05 25.00%
ESMC 0.12 20.00%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
CAFI 0.00 -100.00%
ORIG 24.00 -96.52%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CPWR 1.00 -60.00%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Incyte Corporation (NASDAQ: INCY)

INCY Technical Analysis 4
As on 22nd Sep 2017 INCY Share Price closed @ 110.85 and we RECOMMEND Sell for LONG-TERM with Stoploss of 121.21 & Strong Sell for SHORT-TERM with Stoploss of 127.82 we also expect STOCK to react on Following IMPORTANT LEVELS.
INCY Target for September
1st Target up-side 149.08
2nd Target up-side 157.27
3rd Target up-side 165.45
1st Target down-side 125.74
2nd Target down-side 117.55
3rd Target down-side 109.37
INCY Other Details
Segment EQ
Market Capital 2323686912.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.incyte.com
INCY Address
INCY
Experimental Station
Route 141 & Henry Clay Road
Wilmington, DE 19880
United States
Phone: 302-498-6700
INCY Latest News
Interactive Technical Analysis Chart Incyte Corporation ( INCY NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Incyte Corporation
INCY Business Profile
Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. Its advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received worldwide development and commercialization rights for the compound for inflammatory and autoimmune diseases. In November 2011, JAKAFI became commercially available in the United States and is being marketed in the United States.